| 1.92 0.26 (15.66%) | 09-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.62 |
1-year : | 3.09 |
| Resists | First : | 2.24 |
Second : | 2.65 |
| Pivot price | 2.12 |
|||
| Supports | First : | 1.59 | Second : | 1.32 |
| MAs | MA(5) : | 1.85 |
MA(20) : | 2.14 |
| MA(100) : | 2.21 |
MA(250) : | 2.59 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 12.1 |
D(3) : | 9.8 |
| RSI | RSI(14): 44.2 |
|||
| 52-week | High : | 7.05 | Low : | 1.59 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ XRTX ] has closed above bottom band by 23.6%. Bollinger Bands are 89.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.66 - 2.67 | 2.67 - 2.69 |
| Low: | 1.71 - 1.73 | 1.73 - 1.74 |
| Close: | 1.86 - 1.89 | 1.89 - 1.91 |
XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to advancing and bringing to market medical treatments targeting a range of conditions, including chronic kidney ailments, diabetes, insulin resistance, metabolic syndrome, diabetic nephropathy, and various infections. Their pipeline includes XRx-008, a late-stage clinical program designed to address autosomal dominant polycystic kidney disease (ADPKD). Another key candidate is XRx-101, an agent aimed at reducing uric acid levels in COVID-19 patients, with the goal of mitigating acute kidney injury and related complications. Furthermore, they are developing XRx-221, a series of xanthine oxidase inhibitors intended for the management of diabetic nephropathy. XORTX also collaborates with the Icahn School of Medicine on research investigating acute kidney injury and hyperuricemia among hospitalized COVID-19 patients. The company's operations are headquartered in Vancouver, Canada.
Sat, 19 Sep 2026
XRTX Jumps As XORTX Advances XORLO Gout Program Plans - timothysykes.com
Sat, 19 Sep 2026
XORTX Therapeutics Inc. (XRTX) Stock Price, News, Quote & History - Yahoo Finance
Fri, 18 Sep 2026
XRTX Stock Whipsaws As XORTX Ramps Gout Drug Manufacturing - StocksToTrade
Fri, 18 Sep 2026
A potential new gout pill targets a $700M market as XORTX Therapeutics (XRTX) details its FDA game plan - Stock Titan
Thu, 17 Sep 2026
XORTX (XRTX) Stock Screener: -4.94% Decline on Elevated Volume 2026-09-17 - Exhaustion Gap - CarePlus VietNam
Sat, 12 Sep 2026
XORTX Therapeutics (XRTX) Stock Climbs 16% After Hours: Here's What You Need to Know - webull.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 7.8 (%) |
| Held by Institutions | 4.1 (%) |
| Shares Short | 19 (K) |
| Shares Short P.Month | 24 (K) |
| EPS | -2.58 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.5 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -29.9 % |
| Return on Equity (ttm) | -99.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.19 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -5 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -0.74 |
| PEG Ratio | 0 |
| Price to Book value | 1.25 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.68 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|